感染性自体主动脉瘤腔内与开放修复的系统综述与荟萃分析
腔内修复30天死亡率显著低于开放手术(OR 0.72,95%CI 0.55-0.93),但再感染风险更高(OR 2.56,95%CI 1.71-3.82),1年死亡率无显著差异。
要点
- 腔内修复30天死亡率低于开放手术,但证据确定性极低。
- 腔内修复再感染风险显著高于开放手术。
- 1年死亡率无显著差异,但比较不精确且研究少。
核心结论
- 腔内修复与开放手术相比30天死亡率更低,但该发现对纳入一项大型注册研究敏感,需谨慎解读。
- 腔内修复再感染风险更高,1年死亡率无显著差异但比较不精确。
- 无论选择何种修复策略,仔细的患者选择、延长抗菌治疗和结构化术后监测仍必不可少。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Cochrane Library至2026年6月16日。
- 比较研究采用逆方差随机效应模型(REML估计研究间方差,OR),单臂比例采用logit转换逆方差加权随机效应模型。
- 使用ROBINS-I评估偏倚风险。
主要发现
- 腔内修复30天死亡率显著低于开放手术(OR 0.72,95%CI 0.55-0.93)。
- 1年死亡率无显著差异(8项研究,1,630例患者;OR 1.23,95%CI 0.66-2.29)。
- 再感染风险腔内修复更高(14项研究,1,448例患者;OR 2.56,95%CI 1.71-3.82)。
- 脓毒症复发、再干预和急性肾损伤无显著差异,但比较不精确。
- 单臂分析中,腔内修复后合并30天死亡率为6.5%,1年死亡率为22.4%,再感染率为14.7%。
关键数值与推荐
- 30天死亡率:OR 0.72(95%CI 0.55-0.93),腔内修复 vs 开放手术。
- 1年死亡率:OR 1.23(95%CI 0.66-2.29),无显著差异。
- 再感染:OR 2.56(95%CI 1.71-3.82),腔内修复风险更高。
- 单臂腔内修复:30天死亡率6.5%,1年死亡率22.4%,再感染率14.7%。
- 所有比较结局的证据确定性均为极低(GRADE)。
临床怎么用
- 腔内修复可作为高手术风险患者的早期生存获益选择,但需警惕再感染。
- 无论何种修复策略,均应延长抗菌治疗并实施结构化术后监测。
- 患者选择需权衡早期生存与持久感染控制。
局限性
- 所有纳入研究均为回顾性观察性设计,存在严重适应证混杂风险。
- 比较结局的证据确定性极低(GRADE)。
- 30天死亡率结果对纳入一项大型注册研究敏感。
- 1年死亡率比较不精确且基于少量研究。
- 脓毒症复发、再干预和急性肾损伤比较不精确,不能解读为等效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infective native aortic aneurysms (mycotic) are rare but highly lethal, and the optimal treatment strategy between endovascular repair and open surgical repair (OSR) remains debated because of a persistent trade-off between early survival and durable infection control. We performed a systematic review and meta-analysis comparing early and long-term outcomes of endovascular repair and OSR, complemented by a single-arm meta-analysis characterizing outcomes after endovascular repair. METHODS: PubMed, Embase, and the Cochrane Library were searched from inception to June 16, 2026. Comparative studies were pooled using inverse-variance random-effects models with REML estimation of between-study variance (ORs); single-arm proportions were pooled using logit-transformed, inverse-variance-weighted random-effects models. Risk of bias was assessed with ROBINS-I. Outcomes included 30-day and 1-year all-cause mortality, reinfection (a new or persistent infection requiring antimicrobial therapy or source control), sepsis recurrence (a new episode meeting sepsis criteria after initial clinical resolution), reintervention, and acute kidney injury (AKI). RESULTS: Thirty-five retrospective studies were included: 18 comparative studies (2,853 enrolled patients; 1,305 endovascular repair and 1,548 OSR; 17 of which, comprising 2,836 patients, reported 30-day mortality) and 17 single-arm studies (444 endovascular repair patients; 16 of which reported 30-day mortality). Endovascular repair was associated with significantly lower 30-day mortality than OSR (OR 0.72, 95% CI 0.55-0.93) but not with 1-year mortality (8 studies, 1,630 patients; OR 1.23, 95% CI 0.66-2.29), and with a higher risk of reinfection (14 studies, 1,448 patients; OR 2.56, 95% CI 1.71-3.82). No significant differences were found for sepsis recurrence, reintervention, or AKI, though these comparisons were imprecise and compatible with both clinically meaningful benefit and harm, and should not be interpreted as evidence of equivalence between strategies. In the single-arm analysis, pooled 30-day mortality after endovascular repair was 6.5%, 1-year mortality was 22.4%, and reinfection was 14.7%. CONCLUSIONS: In pooled analysis, endovascular repair was associated with lower early mortality compared with open surgical repair, although this finding was sensitive to the inclusion of a single large registry-based study and should be interpreted with caution. No significant difference in 1-year mortality was observed, but this comparison was imprecise and based on few studies and should not be interpreted as evidence that a survival advantage is absent. Endovascular repair carries a higher risk of reinfection. Careful patient selection, prolonged antimicrobial therapy, and structured postoperative surveillance remain essential regardless of the repair strategy chosen. Certainty of evidence for all comparative outcomes was very low (GRADE), reflecting the observational design, serious risk of confounding by indication, and imprecision of the pooled estimates.
引用
- Coutinho ML, Bregalda Neves CR, Torres IO, et al. Systematic Review and Meta-analysis of Endovascular and Open Surgical Repair for Infective Native Aortic Aneurysms. Ann Vasc Surg. 2026. PMID: 42918568. doi:10.1016/j.avsg.2026.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。